Biomerica Secures Three Key International Patents for inFoods® Technology to Address GERD, Crohn's Disease, and Ulcerative Colitis

Core Insights - Biomerica has received three patent notices of allowance in Europe for its inFoods® Technology, targeting significant markets for GERD, Crohn's Disease, and Ulcerative Colitis, which are valued at over $4 billion,$2.5 billion, and $1.9 billion respectively [1][4][5] Market Potential - The GERD treatment market in Europe exceeds$4 billion annually, with a prevalence of symptoms affecting 8.8% to 25.9% of Europeans weekly [3] - The market for Crohn's Disease treatments in Europe is estimated at $2.5 billion annually, indicating a need for innovative treatment approaches [4] - The European market for Ulcerative Colitis is projected to grow from$1.5 billion in 2023 to over $1.9 billion by 2028 [4] Company Developments - The recent patent allowances mark a significant milestone for Biomerica in enhancing patient care through personalized medical solutions [5] - Biomerica's inFoods® Technology is a diagnostic-guided platform that identifies specific foods triggering symptoms in patients, allowing for personalized dietary plans [6][7] - The company is currently marketing inFoods® for IBS, which is already protected by 15 patents globally, and aims to expand its offerings to include treatments for GERD, Crohn's Disease, and Ulcerative Colitis [5][8] Product Benefits - inFoods® offers a non-drug, dietary-based solution for GERD, presenting a safer alternative to proton pump inhibitors, which are linked to serious health risks [7] - For Crohn's Disease and Ulcerative Colitis, inFoods® supports tailored dietary interventions that may reduce symptom severity and healthcare costs [7]